KR101236227B1 - 에스리카르바제핀 아세테이트 및 그의 사용방법 - Google Patents

에스리카르바제핀 아세테이트 및 그의 사용방법 Download PDF

Info

Publication number
KR101236227B1
KR101236227B1 KR1020077028320A KR20077028320A KR101236227B1 KR 101236227 B1 KR101236227 B1 KR 101236227B1 KR 1020077028320 A KR1020077028320 A KR 1020077028320A KR 20077028320 A KR20077028320 A KR 20077028320A KR 101236227 B1 KR101236227 B1 KR 101236227B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
esricarbazepine
disorder
acetate
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077028320A
Other languages
English (en)
Korean (ko)
Other versions
KR20080015429A (ko
Inventor
아라우조 소아레스 다 실바 파트리시오 마누엘 비에이라
알메이다 조세 루이스 데
Original Assignee
바이알 - 포르텔라 앤드 씨에이 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이알 - 포르텔라 앤드 씨에이 에스에이 filed Critical 바이알 - 포르텔라 앤드 씨에이 에스에이
Publication of KR20080015429A publication Critical patent/KR20080015429A/ko
Application granted granted Critical
Publication of KR101236227B1 publication Critical patent/KR101236227B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077028320A 2005-05-06 2005-05-06 에스리카르바제핀 아세테이트 및 그의 사용방법 Expired - Lifetime KR101236227B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2005/000006 WO2006121363A1 (en) 2005-05-06 2005-05-06 Eslicarbazepine acetate and methods of use

Publications (2)

Publication Number Publication Date
KR20080015429A KR20080015429A (ko) 2008-02-19
KR101236227B1 true KR101236227B1 (ko) 2013-02-21

Family

ID=35464075

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028320A Expired - Lifetime KR101236227B1 (ko) 2005-05-06 2005-05-06 에스리카르바제핀 아세테이트 및 그의 사용방법

Country Status (8)

Country Link
EP (6) EP2380575B1 (https=)
JP (1) JP2008540405A (https=)
KR (1) KR101236227B1 (https=)
CN (1) CN101217959A (https=)
ES (2) ES2534514T3 (https=)
PT (2) PT2380575E (https=)
RU (1) RU2010154008A (https=)
WO (1) WO2006121363A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
BR112012005254A2 (pt) 2009-09-10 2016-03-15 Bial Portela & Ca Sa formulação de suspensão oral, uso da solução de sorbitol em combinação com goma de xantano, processo para preparar uma formulação de suspensão oral compreendendo acetato de eslicarbazepina
TR201008460A1 (tr) 2010-10-15 2012-05-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Eslikarbazepinin saşe formülasyonları.
WO2013032351A1 (en) 2011-08-26 2013-03-07 BIAL - PORTELA & Cª, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
US9814723B2 (en) 2013-02-23 2017-11-14 Lixin Zhang Compositions and methods for prophylaxis and therapy for Meniere's disease
US20140243342A1 (en) * 2013-02-23 2014-08-28 Lixin Zhang Compositions and methods for prophylaxis and therapy for menieres disease
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US6296873B1 (en) 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
ES2314111T3 (es) * 2001-11-12 2009-03-16 Novartis Ag Monohidroxicarbamezepina para uso en la preparacion de un medicamento para el tratamiento del trastorno de afectivo y de atencion y dolor neuropatico.
JP2005538126A (ja) * 2002-08-06 2005-12-15 ノバルティス アクチエンゲゼルシャフト 耳鳴の処置のためのカルボキサミドの使用
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
AU2004212328B2 (en) * 2003-02-17 2008-01-17 Novartis Ag Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB2401605A (en) * 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
MX2007013882A (es) * 2005-05-06 2008-01-28 Portela & Ca Sa Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical pharmacology, 2004, V44, N8, Pages 906-918. *

Also Published As

Publication number Publication date
PT2380573E (pt) 2015-06-11
ES2534514T3 (es) 2015-04-23
EP2380575B1 (en) 2015-02-25
EP2380573A1 (en) 2011-10-26
ES2534560T3 (es) 2015-04-24
CN101217959A (zh) 2008-07-09
KR20080015429A (ko) 2008-02-19
EP2384755A1 (en) 2011-11-09
EP2386303A1 (en) 2011-11-16
WO2006121363A1 (en) 2006-11-16
JP2008540405A (ja) 2008-11-20
EP2380574A1 (en) 2011-10-26
EP2380573B1 (en) 2015-02-25
PT2380575E (pt) 2015-06-17
EP2380575A1 (en) 2011-10-26
EP1879590A1 (en) 2008-01-23
RU2010154008A (ru) 2012-07-10

Similar Documents

Publication Publication Date Title
US11364247B2 (en) Methods of treatment of partial onset seizures using eslicarbazepine acetate
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
KR101236227B1 (ko) 에스리카르바제핀 아세테이트 및 그의 사용방법
RU2488397C2 (ru) Терапевтическое применение эсликарбазепина
CA2607427C (en) Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
JP2016047838A (ja) 酢酸エスリカルバゼピン及び使用方法
Löscher et al. Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy: W. Löscher et al.
RU2417085C2 (ru) Эсликарбазепина ацетат и способы его применения
HK1163554A (en) Eslicarbazepine acetate and methods of use
JP2013237676A (ja) 酢酸エスリカルバゼピン及び使用方法
HK1119960A (en) Eslicarbazepine acetate and methods of use
CN105193822A (zh) 醋酸艾司利卡西平及其应用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100504

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120430

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20121120

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130215

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160127

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160127

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170201

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170201

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180201

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190208

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190208

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20200207

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20200207

Start annual number: 8

End annual number: 8

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20210208

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20210210

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20210210

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20220203

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20220203

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250210

Start annual number: 13

End annual number: 13